Abstract
Background and Aim: Acute esophageal variceal bleeding is a major cause of mortality in portal hypertension. Treatment includes a combination of endoscopic variceal ligation and pharmacological therapy with terlipressin. Terlipressin causes vasoconstriction, reduces splanchnic blood flow and portal pressure. There is a dearth of literature comparing the efficacy & safety profile of continuous infusion to the usual intermittent dosing of terlipressin on a head-to-head basis. We aimed to assess the efficacy of continuous vs intermittent administration of terlipressin for control of acute esophageal variceal bleeding in patients with portal hypertension.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
